secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001493152-25-028126
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharmaceuticals reports favorable GLP safety results for Telomir-1; IND submission targeted Q1 2026
--------------------------------------------------------------------------------

- No treatment-related adverse or dose-limiting toxicities observed across cardiovascular, respiratory, phototoxicity, and repeat-dose safety studies in rats and dogs.
- Telomir-1 well tolerated with consistent systemic exposure; no changes in blood pressure, heart rate, ECG, or body temperature in dogs.
- Final quality assurance review ongoing; no findings preclude advancement into first-in-human studies.
- Ongoing preclinical studies in triple-negative breast cancer and other age-related diseases; targeting IND submission Q1 2026 and first-in-human H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225028126/0001493152-25-028126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225028126/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-028126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer